Formations et évènements

ESMO

L'IFCT à l'ESMO 2025 :

• IFCT-2201 ADAPTABLE en Late-Breaking-Abstract (LBA)
• SMARC4, c-MET and PD-L1 expression in pN2 non-small cell lung cancer from LungART IFCT 0503 trial.
  Speakers: Diego Diaz-Jimenez (Villejuif, France)
• Efficacy of lorlatinib after failure of a first-line ROS1 tyrosine kinase inhibitor (ROS1 TKI) in patients (pts) with advanced ROS1-positive non-small cell lung cancer (ROS1+ NSCLC) (IFCT-2003 ALBATROS)
  Speakers : Michael Duruisseaux (Lyon, France)
• Central pathology review of thymic tumors: updated analysis of diagnostic concordance in the French RYTHMIC cohort
  Speakers Álvaro López Gutiérrez (Salamanca, Spain)